Tamoxifen, ovarian function suppression, and anastrozol were used and reported to be effective strategies for patients with luminal type breast cancer[44–46].The aromatase inhibitor was recommended for postmenopausal ILC patients[47], but there still exist some questions concerning the type and the duration of treatment [48]. The gene discussed is CYP19A1; the disease is breast carcinoma.